Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Type 1 insulin-like growth factor 1 receptor (IGF-1R) targeted therapies demonstrated preclinical efficacy but failed in late-stage clinical trials.
• Toxicity, notably hyperglycemia, arose from overlapping IGF and insulin signaling pathways, hindering development.
• Limited biopsy samples due to halted clinical trials impede correlative studies for response biomarkers.

Purpose of the Study:

• To review the IGF system and the rationale for targeting IGF signaling in cancer.
• To discuss the potential liabilities and toxicities associated with IGF-targeting strategies.
• To identify and explore potential biomarkers for predicting patient response to IGF-targeted therapies.

Main Methods:

• Literature review of preclinical and clinical studies on IGF-1R targeted therapies.
• Analysis of signaling pathways involved in IGF and insulin systems.
• Exploration of existing and potential predictive biomarkers for IGF-driven tumors.

Main Results:

• Preclinical success of IGF-1R inhibitors has not translated to clinical benefit in unselected patient populations.
• Hyperglycemia is a significant toxicity linked to IGF and insulin pathway crosstalk.
• Lack of predictive biomarkers is a major barrier to identifying patients who would benefit from IGF-targeting agents.

Conclusions:

• Effective targeting of IGF signaling requires overcoming significant liabilities and toxicities.
• Development of robust predictive biomarkers is essential for patient stratification and successful clinical application of IGF-1R inhibitors.
• Future strategies must focus on identifying tumors driven by IGF signaling to improve therapeutic outcomes.